• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy.干细胞因子被视为癌症治疗的一个有前景的临床靶点。
Mol Cancer Ther. 2019 Aug;18(8):1337-1340. doi: 10.1158/1535-7163.MCT-19-0605.
2
[The c-kit/Stem Cell Factor in the cancerogenetic process of colon-rectal carcinoma. Biological and clinical aspects].[c-kit/干细胞因子在结直肠癌发生过程中的作用。生物学及临床方面]
Minerva Chir. 2003 Dec;58(6):875-80.
3
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.人干细胞因子抗体[抗SCF]增强人CD34 +耐药髓系白血病细胞中的化疗细胞毒性。
Leuk Res. 2006 Mar;30(3):296-302. doi: 10.1016/j.leukres.2005.06.026. Epub 2005 Aug 19.
4
Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins.利用基于干细胞因子 (SCF) 的重组细菌毒素靶向神经母细胞瘤和结直肠癌中的 c-kit 受体。
Appl Microbiol Biotechnol. 2016 Jan;100(1):263-77. doi: 10.1007/s00253-015-6978-2. Epub 2015 Oct 1.
5
The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review).作为治疗靶点及导致治疗耐药的潜在癌症干细胞因子的甲磺酸伊马替尼酪氨酸激酶受体（综述）
Oncol Rep. 2017 Feb;37(2):647-656. doi: 10.3892/or.2016.5297. Epub 2016 Dec 7.
6
Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells.干细胞因子在常氧条件下可诱导造血细胞中的低氧诱导因子-1α（HIF-1α）。
Biochem Biophys Res Commun. 2008 Dec 5;377(1):98-103. doi: 10.1016/j.bbrc.2008.09.102. Epub 2008 Oct 1.
7
Transglutaminase is a tumor cell and cancer stem cell survival factor.转谷氨酰胺酶是一种肿瘤细胞和癌症干细胞存活因子。
Mol Carcinog. 2015 Oct;54(10):947-58. doi: 10.1002/mc.22375. Epub 2015 Aug 10.
8
The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.干细胞因子/c-kit受体通路增强胰腺癌细胞的增殖和侵袭能力。
Mol Cancer. 2006 Oct 18;5:46. doi: 10.1186/1476-4598-5-46.
9
Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.干细胞因子基因修饰的人自然杀伤细胞系NK-92细胞的特性：对基于NK细胞的过继性细胞免疫治疗的意义
Oncol Rep. 2004 May;11(5):1097-106.
10
Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.甲磺酸伊马替尼通过 PDGFR-β、PDGF-BB、c-Kit 和 SCF 表达对 ZR-75-1 和 MDA-MB-231 细胞系的抗增殖作用。
Int J Mol Med. 2018 Jul;42(1):414-424. doi: 10.3892/ijmm.2018.3590. Epub 2018 Mar 27.

引用本文的文献

1
Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.靶向癌症相关成纤维细胞驱动的LIF/LIFR轴可提高吉西他滨和纳米白蛋白结合型紫杉醇在胰腺癌中的治疗效果。
NPJ Precis Oncol. 2025 Aug 22;9(1):296. doi: 10.1038/s41698-025-01046-w.
2
Targeting LIF/LIFR signaling in cancer.靶向癌症中的LIF/LIFR信号通路。
Genes Dis. 2021 Apr 29;9(4):973-980. doi: 10.1016/j.gendis.2021.04.003. eCollection 2022 Jul.
3
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.LIF/LIFR 轴在癌症中的多效性作用、功能和靶向治疗：旧观念的新视角。
Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188737. doi: 10.1016/j.bbcan.2022.188737. Epub 2022 Jun 6.
4
IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment.白细胞介素 6 细胞因子家族：乳腺癌预防和治疗的潜在靶点。
Int J Mol Sci. 2022 Feb 5;23(3):1809. doi: 10.3390/ijms23031809.
5
An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy.工程化配体陷阱抑制白血病抑制因子作为胰腺癌治疗策略。
Commun Biol. 2021 Apr 12;4(1):452. doi: 10.1038/s42003-021-01928-2.

本文引用的文献

1
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.阻断白血病抑制因子作为一种治疗 KRAS 驱动的胰腺癌的方法。
Nat Commun. 2019 Jul 11;10(1):3055. doi: 10.1038/s41467-019-11044-9.
2
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy.LIF 调控肿瘤相关巨噬细胞中的 CXCL9，防止 CD8 T 细胞浸润肿瘤，从而削弱抗 PD-1 治疗效果。
Nat Commun. 2019 Jun 11;10(1):2416. doi: 10.1038/s41467-019-10369-9.
3
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.EC359：一种针对三阴性乳腺癌致癌性 LIFR 信号的首创小分子抑制剂。
Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.
4
Bazedoxifene as a novel strategy for treatment of pancreatic and gastric adenocarcinoma.巴多昔芬作为治疗胰腺和胃腺癌的新策略。
Oncotarget. 2019 May 7;10(34):3198-3202.
5
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.针对胰腺癌治疗和监测的 LIF 介导的旁分泌相互作用。
Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.
6
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.IL1 诱导的 JAK/STAT 信号被 TGFβ拮抗，从而塑造胰腺导管腺癌中 CAF 的异质性。
Cancer Discov. 2019 Feb;9(2):282-301. doi: 10.1158/2159-8290.CD-18-0710. Epub 2018 Oct 26.
7
Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin.肿瘤分泌的白血病抑制因子引起的恶病质相关脂肪丢失被降低的瘦素所抵消。
JCI Insight. 2018 Jul 26;3(14). doi: 10.1172/jci.insight.121221.
8
LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker.LIF 驱动胰腺癌中的神经重塑，并提供了一种新的候选生物标志物。
Cancer Res. 2018 Feb 15;78(4):909-921. doi: 10.1158/0008-5472.CAN-15-2790. Epub 2017 Dec 21.
9
TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.前列腺癌细胞中TLR9的表达及白血病抑制因子的分泌会刺激多形核髓源性抑制细胞的积聚及活性。
J Leukoc Biol. 2017 Aug;102(2):423-436. doi: 10.1189/jlb.3MA1016-451RR. Epub 2017 May 22.
10
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.胰腺癌中不同的炎性成纤维细胞和肌成纤维细胞群体。
J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy.

作者信息

Shi Yu, Hunter Sean, Hunter Tony

机构信息

Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California.

Cancer Biology Program, Stanford University, Stanford, California.

出版信息

Mol Cancer Ther. 2019 Aug;18(8):1337-1340. doi: 10.1158/1535-7163.MCT-19-0605.

DOI:10.1158/1535-7163.MCT-19-0605
PMID:31371576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8074628/
Abstract
摘要